- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.02. | Alnylam changes to heart drug trial spark doubts, sinking shares | ||
| 15.02. | Intellia, ReCode partner on genetic medicines for cystic fibrosis | ||
| 15.02. | Aurinia to cut research after sale process fails to find a buyer | ||
| 15.02. | Versant-backed Firefly Bio wants to make the next generation of ADCs | ||
| 14.02. | Ipsen drug approved by FDA for early pancreatic cancer | ||
| 14.02. | Sage offers details on launch of new postpartum depression pill | ||
| 14.02. | LianBio to shut down, return cash to investors | ||
| 14.02. | Hunting a non-opioid painkiller, a biotech startup reveals plans to chase Vertex | ||
| 13.02. | BioAge raises $170M to back Phase 2-ready obesity drug | ||
| 13.02. | Biogen has a fuzzy line of sight on prized Alzheimer's drug | ||
| 13.02. | ADC startup ProfoundBio, led by Seagen veterans, raises $112M | ||
| 13.02. | Two GV partners on biotech's reset and building their next drug startups | ||
| 13.02. | Kalvista pill succeeds in late-stage study for rare swelling disorder | ||
| 12.02. | Alys launches with $100M and a pipeline of skin disease drugs | ||
| 12.02. | CSL heart drug misses goal in large study | ||
| 12.02. | Gilead to buy CymaBay in $4.3B deal for liver disease drug | ||
| 12.02. | Chart a course for sustainable growth | ||
| 09.02. | Takeda speeds narcolepsy drug to late-stage testing | ||
| 09.02. | Kyverna CEO Peter Maag on courting investors in a 'volatile' IPO market | ||
| 09.02. | Pharma CEOs, pressed by Senate panel, refuse to commit to price cuts | ||
| 08.02. | Neurona raises another $120M for brain disease cell therapies | ||
| 08.02. | BioNTech partners with Autolus to boost cell therapy manufacturing | ||
| 07.02. | BridgeBio sells partial rights to dwarfism drug for $100M | ||
| 07.02. | Obesity drug mania takes over Amgen's earnings call | ||
| 07.02. | AstraZeneca to invest $300M in US cell therapy plant |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
